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Dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG) and 1,2-Dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(Lissamine rhodamine B sulfonyl) (ammonium salt) (DPPE-Rh) were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
[folate(polyethylene glycol)-3350] (DSPE-PEG3350-Folate) was synthesized according to the literature.[1] 
Cholesterol (Chol), arsenic trioxide (As2O3), sodium arsenite (NaAsO2), cisplatin (cisPt), silver acetate (Ag(OAc)), 
folic acid (FA), paraformaldehyde, 2-[4-(2-hydroxyethyl)-1-piperazine]ethanesulfonic acid (HEPES), 2-[N-
Morpholino]ethanesulfonic acid (MES), Bicine, sucrose, sodium dodecyl sulfate (SDS), phenazine methosulfate 
(PMS), human insulin solution, and Sephadex G50 were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Sodium nitrate was from Mallinckrodt (Kentucky, USA). 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was from Promega (Madison, WI, USA). RPMI-
1640, folate-deficient RPMI-1640, fetal bovine serum (FBS) were from INVITROGEN-GIBCO (Carlsbad, CL, 
USA). Charcoal dextran–stripped fetal bovine serum (cds-FBS) was from Atlanta Biologicals, Inc. (Lawrenceville, 
GA, USA). Eagle's Minimum Essential Medium (EMEM) was from the American Type Culture Collection 
(ATCC) (Manassas, VA, USA). L-Glutamine, penicillin-streptomycin, and phosphate-buffered saline (PBS) were 
from MEDIATECH (Herndon, VA, USA). Amphotericin B from Biologas (Montgomery, IL, USA).  
 
Coencapsulation of Arsenic- and Platinum-based Drugs within Liposomes 
 
(a) Preparation of aqua-cisPt gradients 
The acetate solution of aqua-cisPt (300 mM [cis-(NH3)2Pt(OH2)2](OAc)2) was prepared as previously reported.[2] 
Briefly, 360 mg cisPt (cis-(NH3)2PtCl2) was mixed with 370 mg Ag(OAc) in 4 mL MQ-H2O at 50ºC in the dark for 
4-5 h. The mixture was then kept at 20ºC overnight before filtered through a 0.2 µm syringe filter (cellulose acetate 
membrane, Nalgene) to remove the white AgCl precipitate. The obtained pale yellow solution (pH 5.1) was sealed 
and kept at 4ºC in the dark and used within two weeks. 
 
Lipid mixtures of DPPC/DOPG/Chol with various molar ratios (51.4/3.6/45, 86.4/3.6/10, and 96.4/3.6/0) were 
dissolved in chloroform. For rhodamine (Rh)-labeled liposomes, 0.5% DPPE-Rh was included. The chloroform 
was then removed by rotary vacuum evaporation to form lipid film on the vial, which was subsequently placed 
under a high vacuum overnight to remove any residual solvent. The dried lipid film was hydrated in 300 mM aqua-
cisPt acetate (Figure S1a) to form multilamellar vesicles (MLVs), which were further subjected to 7 freeze-and-
thaw cycles (freezing in a ethanol/dry-ice bath and thawing in a water bath at 50ºC).[3] The liposomes were then 
extruded with a manual mini-extruder (Avanti Lipids, AL, USA), 10 times through two stacked polycarbonate 






filters of 0.1 µm pore size at 40ºC. Extruded liposomes in the aqua-cisPt acetate were then fractionated on 
Sephadex G-50 columns (1 mL sample volumes were placed on columns with at least a 20 mL column bed) 




Figure S1. The procedure of coencapsulating arsenic- and platinum-based drugs into liposomes. (a) Hydration of dried
lipids in 300 mM aqua-cisPt acetate (pH 5.1). Self-assembled liposomes are then reduced to 100 nm by extrusion. (b) Gel
exclusion for exchanging external buffer into 300 mM sucrose, 10 mM MES, pH 5.1. (c) Liposome suspension is added with
As2O3 solution and kept at 50°C and pH 6.6-6.9 for 11 h. (d) The influx of As(OH)3 into liposomes to form complex(As, Pt),
accompanied by the efflux of acetate acids (HAc). Removal of excess of external As(OH)3 by gel exclusion with 300 mM
sucrose, 10 mM MES, pH 7.4-8.0, followed by adjusting the pH of final liposome product back to 6.1-6.4. 
(b) Arsenic loading. Typically, for 30 mg of DPPC/DOPG/Chol, 51.4/3.6/45 mol%, after removal of 
extraliposomal platinum species using the Sephadex G-50 column (Figure S1b), 180 µL of arsenic trioxide solution 
(As 300 mM) was added to these aqua-cisPt acetate-containing liposomes at an initial As/lipid molar ratio of ~4 
and a lipid concentration of ~5 mM, and the pH of mixture was adjusted to 6.6-6.9 (Figure S1c). Samples were 
incubated at 50ºC with frequent vortexing. At various time points, 100 µL aliquots were passed through Sephadex 
G-50 with the same buffer at pH 7.4-8.0 to remove unencapsulated arsenic and platinum species. The 
concentrations of lipids (P) and of encapsulated As and Pt in the excluded fractions were determined with an 
inductively coupled plasma optical emission spectrometer (ICP-OES) (Vista MPX, USA).[4] The molar ratios of 
As/lipid, Pt/lipid and As/Pt were calculated and used to assess extent of loading at each time point. 
 
Figure 1c shows the dependence of As/lipid, Pt/lipid, and As/Pt molar ratios as a function of incubation time during 
arsenic loading into liposomes at 50ºC in response to the transmembrane gradient of aqua-cisPt acetate. The 
As/lipid molar ratio rapidly increased within the first 3 h indicating rapid arsenic loading, and achieved equilibrium 
after 11 h at molar ratios of As/lipid = 0.66 and As/Pt = 1.4 and a half-time of 40 min. 
 
Figure S2 shows that the extent of arsenic loading into liposomes increased with increasing concentration of 
intraliposomal aqua-cisPt acetate. When 100 mM aqua-cisPt acetate was used as the intraliposomal media, a value 
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Figure S2. Arsenic-loading extent is dependent on the concentration of intraliposomal aqua-cisPt acetate.
DPPC/DOPG/Chol = 51.4/3.6/45 mol%; outer buffer: 120 mM or 300 mM sucrose, 10 mM MES, pH 6.7, 50ºC for 11 h, with
an initial As-to-lipid molar ratio of 4.0. 
(c) Determination of intraliposomal drug concentration. The kinetics of arsenic loading into 100-nm-
liposomes using 300 mM aqua-cisPt acetate as the intraliposomal medium revealed little reduction in the Pt/lipid 
molar ratio during the loading period of 11 h at 50ºC (Figure 1c). This indicates that the platinum species are 
efficiently retained inside the liposomes and that little leakage occurred (< 10%). The molar ratio of Pt/lipid 0.48 ± 
0.06 (n = 7) at 11 h can be assumed to correspond to 300 mM platinum species within one single liposome of 
NB(As, Pt). We further found that As/Pt = 1.3 ± 0.1 (n = 7), indicating intraliposomal As = 390 ± 30 mM (n = the 
number of independent experiments). These values are close to those expected for an encapsulated volume of 1.5 
L/mol phospholipid.[5] The mean sizes of NB(As, Pt) were determined as 112 ± 9 nm by dynamic light scattering 
on a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). The average intraliposomal core of NB(As, Pt) can 
be assumed as a sphere with a diameter of ~100 nm and a volume of 5.23 x 10-19 L, considering that the thickness 
of a lipid bilayer is 4-6 nm.[6, 7] Thus, there are ~12 x 104 As atoms and ~9 x 104 Pt atoms per liposome in NB(As, 
Pt). 
 
Transmission Electron Microscopy (TEM) 
Liposome samples were stained with 2% uranyl acetate on 400-mesh copper grids (carbon-coated and formvar-
covered, Ted Pella, Inc., USA), and air-dried overnight before TEM analysis at 200 kV, magnification 40,000 x 
(Hitachi HF2000, Hitachi High-Technologies, Japan). For visualization of the inorganic cores within the liposomes, 
some liposome samples were left unstained to avoid the influence of the electron density of uranyl acetate.[4, 8, 9] 
These unstained samples were analyzed for arsenic and platinum components within the liposomal cores by 
energy-dispersive X-ray analysis (EDX) (Figure 2). 
 
Stability of Arsenic and Platinum Liposomes  
Liposome stability was evaluated with a drug release assay. NB(As, Pt) samples were kept at 4ºC or 37ºC at 
different pHs with 1 mM lipid. An extraliposomal buffer of 300 mM sucrose (or NaNO3) and 10 mM MES was 
used for maintaining the pH at 5.0 and 6.1; for pH 7.4 and 8.2, 20 mM Bicine was additionally added; and for pH 
4.0, 20 mM acetic acid was additionally added. The pH of these dispersions were re-adjusted to the indicated 
values with HNO3 or NaOH solution. For serum samples, NB(As, Pt) were mixed with FBS in a volume/volume 
ratio of 2:8 (80% serum) with 1 mM lipid and kept at 37ºC. At various time points, aliquots were passed over a 
Sephadex G-50 column to remove arsenic and platinum species which had leaked from liposomes. The excluded 
volume fractions containing liposomes were digested with concentrated HNO3 (trace metal grade, Fisher Scientific) 
before ICP-OES analysis for determination of the drug-to-lipid molar ratios. The drug release percentage was 
calculated as [(ro-ri)/ro] x 100%, where ro is the initial drug-to-lipid molar ratio and ri the drug-to-lipid molar ratio at 
a specific time point.[4] The results are compared in Figures 3, S3 and S4. 
 
Figure S3 shows stable encapsulation of NB(As, Pt) (DPPC/DOPG/Chol = 51.4/3.6/45 mol%) with little arsenic 
and platinum release (< 5%) within the range of pH 4.0-8.2 after 3 days at 37ºC. 
 
Figure S4 compares drug release of NB(As, Pt) in serum with three lipid compositions: DPPC/DOPG/Chol = 
51.4/3.6/45 mol% (a), 86.4/3.6/10 mol% (b), and 96.4/3.6/0 mol% (c), and their cytotoxic effects on SU-DHL-4 




























































Figure S3. Drug release of NB(As, Pt) at 37ºC as a function of time at pH 7.4 (a) and after 72 h at various pHs (b).
DPPC/DOPG/Chol = 51.4/3.6/45 mol%. 
 













































































































Figure S4. Comparison of drug release of NB(As, Pt) at 37ºC in 80% FBS with various lipid compositions:
DPPC/DOPG/Chol = 51.4/3.6/45 (a), 86.4/3.6/10 (b), 96.4/3.6/0 (c), mol%. The faster drug release results in the higher
cytotoxic effects (IC50) on SU-DHL-4 (d, 72 h) and MDA-MB-231 cells (e, 96 h). 
 
Preparation of Folate-targeted Arsenic and Platinum Liposomes 
The folate-targeting ligand, DSPE-PEG3350-Folate, was incorporated into the lipid bilayer of pre-formed NB(As, Pt) 
using the “post-insertion” technique.[10] Typically, 20 µL of DSPE-PEG3350-Folate (5 mg/mL chloroform solution) 
was placed in a glass tube and the chloroform was removed by rotary evaporation. The resultant lipid film was 
subsequently placed under a high vacuum overnight to remove any residual solvent. To this dry lipid film was 
added a suspension of pre-formed NB(As, Pt) (mean size 112 ± 9 nm) at a molar ratio of folate/lipid = 0.7%, in 300 
mM sucrose, 10 mM MES, pH 6.4. The mixture was kept at 50ºC for 1.5 h with stirring and then passed through a 
Sepharose CL-4B column to remove any leaked drugs and unincorporated DSPE-PEG3350-Folate. The obtained 
folate-targeted liposomes (f-NB(As, Pt)) were analyzed by ICP-OES for arsenic, platinum and lipid concentrations, 
yielding molar ratios of 0.59 ± 0.01 for As/lipid and 0.48 ± 0.02 for Pt/lipid. The mean liposome diameters were 
determined as 129 ± 4 nm by dynamic light scattering on a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK), 
17 nm larger than those of NB(As, Pt). The folate content of f-NB(As, Pt) preparations was determined by lysing 
the liposomes with 5% SDS and measuring the UV absorbance at 285 nm.[11] All samples in 5% SDS were 
prepared in a 96-well half-area microplate (Greiner Bio-one GmbH, Germany), 150 µL per well. To ensure every 
well had the same background, standard solutions (0-0.4 µM free folate acid (FA)) were additionally mixed with 
NB(As, Pt) at the same lipid level as in f-NB(As, Pt). The plate was then kept in the dark for 24-48 h and 
centrifuged at 500 g, 5-10 min (to eliminate bubbles) before reading the absorbance at 285 nm. Figure S5 is a 
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typical standard curve of FA absorbance vs. concentration in the presence of 0.5 mM lipids from NB(As, Pt) and 
5% SDS. The FA concentration of f-NB(As, Pt) was derived from the standard curve, giving the molar ratio of 0.56 
(± 0.15)% folate/lipid. 
 





















Figure S5. Standard curve of FA absorbance at 285 nm vs. concentration in aqueous solution in the presence of 0.5 mM
lipids from NB(As, Pt) and 5% SDS. 
 
Cell Culture  
SU-DHL-4 (human lymphoma B cells) was from the Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH (DSMZ, Braunschweig, Germany). MM.1S (human multiple myeloma B cells) was previously established 
in one of our laboratories (N. L. Krett and S. T. Rosen). IM-9 (human lymphoblast B cells), MDA-MB-231 (human 
breast adenocarcinoma cells), OVCAR-3 (human ovary adenocarcinoma cells), KB (human nasopharyngeal 
epidermal carcinoma cells, FR+), and MCF-7 (human breast carcinoma cells, FR-)[12, 13] were purchased from ATCC 
(Manassas, VA, USA). 
 
All Cells were maintained at 37ºC in an incubator with 5% CO2 and harvested in the exponential phase of growth. 
SU-DHL-4, IM-9, and MM.1S cells were cultured in RPMI-1640 supplemented with 10% FBS, 2 mM glutamine, 
100 units/mL penicillin-streptomycin, and 2.5 µg/mL Amphotericin B. MDA-MB-231 cells were cultured in 
DMEM/F12 supplemented with 5% cds-FBS, 2 mM glutamine, 100 units/mL penicillin-streptomycin, and 0.1% 
human insulin solution. OVCAR-3 cells were cultured in RPMI-1640 supplemented with 20% FBS, 100 units/mL 
penicillin-streptomycin, and 0.1% human insulin solution. MCF-7 cells was cultured in EMEM supplemented with 
10% FBS, 2 mM glutamine, 100 units/mL penicillin-streptomycin and 2.5 µg/mL Amphotericin B. KB cells were 
cultured in EMEM supplemented with 10% FBS and 50 units/mL penicillin-streptomycin. For folate-targeting 




(a) MTS assay. The in vitro cytotoxicities of NB(As, Pt), NB(Pt), As2O3, aqua-cisPt acetate and cisPt were 
determined using the MTS cell proliferation assay as described previously.[15] Briefly, SU-DHL-4 and IM-9 
(40,000 cells/mL), and MM.1S (250,000 cells/mL) were treated with drugs and plated in quadruplicate (100 
µL/well) onto 96-well plates. For MDA-MB-231 and OVCAR-3, 20,000 cells/mL were plated in quadruplicate 
(100 µL/well) onto 96-well plates, incubated overnight and then treated with drugs. After incubation for the 
indicated period at 37ºC, the MTS/PMS solution (20 µL/well) was added to each well and the plates were further 
incubated for 4 h at 37ºC before reading the absorbance at 490 nm. Cell growth rates were expressed as a function 
of drug concentration on a logarithmic scale. The IC50 values (the drug concentration required for 50% inhibition of 
cell growth) were determined by fitting to a sigmoidal dose-response curve using Origin 6.0 software (Microcal 
Software, Inc., Northampton, USA). In the case of the 1.5 h (Figure S6b) or 2 h (Figure S7b) time periods, the cells 
treated with drugs were first incubated for 1.5 h or 2 h at 37ºC, then washed twice with PBS to remove un-
associated drugs or liposomes, and further incubated up to 48 h (Figure S6b) or 72 h (Figure S7b) in drug-free 
medium, followed by the MTS assay. The data are shown in Tables 1 and S1, and Figures S6-8. 
 
Figure S6 shows that for SU-DHL-4 cells, after a 48-h incubation, NB(As, Pt) (IC50 20.6 µM As or 15.6 µM Pt) 
exhibited attenuated cytotoxicity relative to the free drugs As2O3 (3.7 µM As), aqua-cisPt (5.5 µM Pt) and cisPt 
(3.5 µM Pt). Notably, NB(As, Pt) was three times more cytotoxic than NB(Pt) (42.4 µM Pt), indicating the 
bioavailability of both arsenic and platinum species from NB(As, Pt). At long incubation times (> 48 hrs, i.e.), the 
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cytotoxicities of NB(Pt, As) increased greatly, approaching those of As2O3, aqua-cisPt and cisPt (Figure S6b), 
consistent with gradual release of the drugs at 37ºC in serum (Figure 3b). 
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Figure S6. (a) Cytotoxic effects of NB(As, Pt), NB(Pt), aqua-cisPt and As2O3 on SU-DHL-4 cells after a 48 h incubation. For
NB(As, Pt), NB(Pt), and aqua-cisPt, M = Pt; for As2O3, M = As. (b) Cytotoxicities (IC50) of NB(As, Pt), As2O3, cisPt, and aqua-
cisPt after incubation for 1.5 h, 24 h, 48 h, and 72 h. DPPC/DOPG/Chol = 51.4/3.6/45 mol%. 







































Figure S7. (A) Cytotoxic effects of NB(As, Pt), NB(Pt), aqua-cisPt, and As2O3 on MDA-MB-231 cells after a 72 h incubation.
For NB(As, Pt), NB(Pt) and aqua-cisPt, M = Pt; for As2O3, M = As. (C) Cytotoxicities (IC50) of NB(As, Pt), As2O3, cisPt, and
aqua-cisPt after incubation for 2 h, 48 h, 72 h, and 96 h. DPPC/DOPG/Chol = 51.4/3.6/45 mol% 
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 NB(Pt), IC50 = 25.1 µM (Pt)
 NB(As, Pt), IC50 = 7.9 µM (As) or 6.0 µM (Pt)
 cisPt, IC50 = 1.43 µΜ (Pt)
 As2O3, IC50 = 0.58 µM (As)
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Figure S8. Cytotoxic effects of NB(As, Pt), NB(Pt), cisPt and As2O3 on MM.1S (a) and IM-9 (b) cells after a 72 h incubation.
For NB(As, Pt), NB(Pt), and cisPt, M = Pt; for As2O3, M = As. DPPC/DOPG/Chol = 51.4/3.6/45 mol% 
Figure S7 shows that for MDA-MB-231 cells, after a 72 h incubation, NB(As, Pt) (IC50 35.0 µM As or 26.6 µM Pt) 
exhibited attenuated cytotoxicity relative to the free drugs As2O3 (10.0 µM As), aqua-cisPt (17.9 µM Pt) and cisPt 
(14.0 µM Pt). Notably, NB(As, Pt) was 7 times more cytotoxic than NB(Pt) (> 200 µM Pt), indicating the 
bioavailability of both arsenic and platinum species from NB(As, Pt). At long incubation times (> 72 hrs, i.e.), the 
cytotoxicities of NB(As, Pt) increased greatly, approaching those of As2O3, aqua-cisPt and cisPt (Figure S7b), 
consistent with gradual release of the drugs at 37ºC in serum (Figure 3b). 
 
Similar anticancer activities of NB(As, Pt) were observed for other lymphoma (IM-9), multiple myeloma (MM.1S), 





Table S1. Comparison of cytotoxicities (IC50) of aqua-cisPt and cisPt towards human tumor cells  
 
IC50 (Pt/µM)[b]
Cell lines[a] Aqua-cisPt CisPt 
SU-DHL-4  5.5 ± 0.4 3.5 ± 0.8 
IM-9 1.0 ± 0.01 0.6 ± 0.2 
MDA-MB-231  17.9 ± 0.1 14.0 ± 1.8 
OVCAR-3  2.6 ± 0.8  2.0 ± 0.01 
[a] 48 h-drug treatment for SU-DHL-4 and IM-9, and 72 h-drug treatment for MDA-MB-231 and OVCAR-3 cells. [b] IC50 (± SD) 
values are based on two independent experiments. 
 
(b) Guava ViaCount assay 
Note: The MTS assay is one of most high throughput and economical assays for detecting viability of cancer 
cells.[15] In the case of treatment with f-NB(As, Pt), however, it appeared that the folate moiety interfered with the 
reactions of MTS/PMS agents, and seriously impaired accuracy of cell viability. A different assay, Guave 
ViaCount,[16, 17] was thus applied here for determination of the cytotoxicity of folate-targeted liposomes against KB 
and MCF-7 cells. This assay provides repeatable and reliable results[13] although it is much more time-consuming 
and expensive than the MTS assay. 
 
Cells were first plated in 48-well plates at a density of 30,000-60,000 cells/mL, 0.2 mL per well. After 24 h at 
37°C, the media were replaced with drug solutions. Cells were thus incubated with drugs continuously for 72 h, or 
exposed to drugs for 3 h at 37°C, then washed with PBS x 2 and further incubated up to 72 h in drug-free medium. 
The same Pt concentrations of aqua-cisPt were used as in f-NB(As, Pt). Cell viability was determined by Guave 
ViaCount,[13, 16, 17] using a Guava EasyCyte Mini flow cytometer (Guava Technologies, Hayward, CA). Briefly, 
cells, after released from plates by trypsinization, were stained with the Guava Viacount agent, which contains two 
fluorescent dyes, one cell permeable and one impermeable. This allows viable and dead cell numbers to be 
accurately determined by Guava Viacount software. Cell growth rates were expressed as a function of drug 
concentration on a logarithmic scale. The IC50 values (the drug concentration required for 50% inhibition of cell 
growth) were determined by fitting to a sigmoidal dose-response curve using Origin 6.0 (Microcal Software, Inc., 
Northampton, USA). The data are shown in Figure 5 and Table 2. 
 
Confocal Microscopy for Visualization of Cellular Liposome Uptake  
Cells were first plated, 24-48 h before each experiment, on 22-mm coverslips inside 6-well plates. Cells were then 
exposed to rhodamine (Rh)-labeled liposomes at 37°C for 3 h at a lipid concentration of 40 µM and an arsenic 
concentration of 24 µM. After drug-containing medium removal, cells were washed with PBS x 4 and fixed with 
PBS-buffered 4% paraformaldehyde at 20°C for 5 min, then washed with PBS x 1. Next, the coverslips were 
mounted on slides coated with PBS. Microscopic visualization of cells was performed using a Zeiss confocal laser 
scaning microscope (Carl Zeiss LSM 510, Jena, Germany). For rhodamine (Rh), maximum excitation was obtained 
from the 543-nm line of a He-Ne laser, and fluorescence emission intensities > 570 nm were observed using a long-
pass barrier filter LP-570. A water immersion objective, C-Apochromat 63 x 1.2 W corr. (Zeiss), was used. Cells 
were also imaged by light microscopy using differential interference contrast (DIC). The data are shown in Figures 
5a-d. 
 
Quantitative Analysis of Drug Uptake 
Cells were first plated, 24 h before each experiment, in 6-well plates with 500,000 cells per well. Cells were then 
exposed to 10 µM arsenic as free drug or within liposomes for 3 h at 37°C. The same Pt concentration (8 µM) of 
aqua-cisPt were used as in f-NB(As, Pt). After washing with PBS to remove non-associated drugs, cells were 
released from tissue culture plates with 0.05% trypsin/0.02% EDTA (Invitrogen), followed by 3 x PBS washing 
(centrifugation, 500 g, 5 min, 4ºC). Two control samples were taken for cell number determination with the Guava 
ViaCount Assay,[13, 17] using a Guava EasyCyte Mini flow cytometer (Guava Technologies, Hayward, CA). Cell 
pellets from each well were digested with 100 µL concentrated nitric acid (trace metal grade, Fisher Scientific) for 
measurement of arsenic (As) and platinum (Pt) concentrations by inductively coupled plasma mass spectroscopy 
(ICP-MS, X Series II, Thermo Electron, UK). Cell-associated drug was expressed as As and Pt atoms per cell. The 





Table S2. Comparison of cellular uptake of various drug formulations to tumor cells  
 
Cellular uptake (x107 atoms/cell)[a]
KB (FR+) MCF-7 (FR-) Formulations 
As Pt As Pt 
As2O3 17.1 ± 1.0  9.4 ± 2.3  
NB(As, Pt) 3.2 ± 0.4 0.26 ± 0.06 1.7 ± 0.3 0.18 ± 0.06 
f-NB(As, Pt) 131.3 ± 8.1 108.9 ± 18.3 10.2 ± 2.3 7.3 ± 1.7 
f-NB(As, Pt)  
+ 2 mM FA  
5.8 ± 1.7 1.8 ± 1.4 2.8 ± 1.5 0.7 ± 0.7 
Aqua-Pt  0.4 ± 0.1  0.24 ± 0.07 
[a] Cellular uptake was measured by ICP-MS after cells were exposed to drugs for 3 h at 37°C. The mean values and standard 
deviations (± SD) are based on three independent experiments. 
 
 
Arsenic and Platinum Precipitates from Bulk-Mixed Aqua-cisPt acetate with As(OH)3
5.6 mL of aqua-cisPt acetate (Pt 300 mM, pH 5.1) were mixed with 22.4 mL As2O3 (As 300 mM, pH 12.5). This 
mixture (As/Pt = 4 mol/mol) was placed into seven falcon-tubes (4 mL/each). The pH of each tube was adjusted 
from 12.1 to 1.7, 2.6, 3.6, 4.5, 5.5, 6.5, and 8.1, respectively, using HNO3 and NaOH solutions. The tubes were 
sealed and incubated at 50°C for 4 h and then at 20°C overnight. The pale-yellow precipitate was collected from 
each tube, washed thoroughly with MQ-H2O and dried over P2O5. The final pH of the supernatant in each tube was 
measured, and the As/Pt molar ratio of the dried precipitate was determined by ICP-OES in 3% HNO3 (Figure S9). 
We found lower pH conditions facilitated the precipitate formation at 50ºC; when pH > 6.0 (tubes 6 and 7), the 
amount of precipitate was too small to collect. All precipitates were air stable at room temperature for months, and 
not soluble in many organic solvents, such as DMSO, DMF, methanol, chloroform, acetone, acetonitrile, benzene, 
etc. They are sparingly soluble in water, perhaps accompanied by hydrolysis: the starting compounds tend to 
reform through dissociation of soluble As(OH)3 and cis-[(NH3)2Pt(OH2/OH)2]n+ species from the precipitate into 
water. These precipitates easily dissolve in strong acids and bases (such as 1% HNO3 or HCl, 0.5 M NaOH). 
 


























Figure S9. The pH dependence of As/Pt molar ratios in precipitates produced upon mixing aqua-cisPt acetate with As(OH)3
at 50ºC, initial As/Pt = 4 mol/mol. 
When pH > 3.5, the precipitates had molar ratios of As/Pt less than 2 (Figure S9), likely due to the competitive 
binding of hydroxide (OH-) towards the Pt centers.[2]  When pH > 6, the hydroxo cisPt species became 
predominant,[18] resulting in significant reduced amounts of arsenic and platinum complexes (Figure S9).[19] 
 
Arsenic and Platinum Nanoparticulates within Liposomes 
The dispersion of NB(As, Pt) (20 mL) was centrifuged (2100 g, 30 min, 20ºC) to collect liposome nanoparticles. 
The NB(As, Pt) pellet was re-suspended in 10 mL MQ-H2O and centrifuged at 2100 g for 20 min to pellet 
liposomes. This washing step (with H2O) was repeated three times for complete removal of soluble salts. The wet 
liposome pellet was then freeze-dried under high vacuum. Chloroform (8 mL) was added to this dried mixture and 
the insoluble complex(As, Pt) was collected after centrifugation. This step was repeated 5 times for complete 
removal of the lipids. The obtained complex(As, Pt)1.36 (As/Pt = 1.36 molar ratio) was pale-yellow and stable in air 
at room temperature for months; it had a similar appearance and physical properties to the precipitates generated by 
bulk-mixing aqua-cisPt acetate with As2O3 solution at pH 4-5. This powder sample was analyzed by X-ray 
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photoelectron spectroscopy (XPS) under the Omicron ESCA Probe (Omicron Nanotechnology, Taunusstein, 
Germany) (Figure S10), and its results were compared with those of As2O3, NaAsO2, cisPt, and aqua-cisPt acetate 
(Table S3). All samples (powder) were embedded into adhesive carbon tapes and mounted in the analysis chamber. 
The spectra were acquired with X-ray illumination (beam energy 14 eV) under high vacuum (1.0 x 10-9 mbar). The 
surface charge was neutralized with the electron gun. The data were analyzed by the ESI software (Version 2.4, 

































































































Figure S10. (a) XPS wide scan of complex(As, Pt)1.36 separated from NB(As, Pt). The C1s peak is from the carbon tape. 
XPS narrow region scans of Pt(4f) and As(3d) for complex(As, Pt)1.36 from NB(As, Pt) relative to those of aqua-cisPt acetate 
(b) and As2O3 (c).  
 
Table S3. XPS binding energy (eV)[a] of various arsenic and platinum formulations 
 
Formulations Pt (4f7/2) As (3d) N1s O1s 




NaAsO2  44.4 ± 0.6 
44.2[20] 
 530.7 ± 0.3 
 
cisPt 73.9 ± 0.01 
73.2[20] 
 400.6 ± 0.6 
400.2[20] 
 
Aqua-cisPt acetate 74.0 ± 0.4  400.7 ± 0.5 531.9 ± 0.5 
NB(As, Pt) 73.5 ± 0.4 44.9 ± 0.5 400.4  ± 0.5 531.3 ± 0.3 
[a] The values (± SD) of Binding Energy (eV) are based on 2-5 independent experiments. 
Since the binding energy of core electrons of an element is sensitive to the chemical environment, the chemical 
shift of binding energy has been used to study the chemical status of elements,[20] including As[21] and Pt[22] 
compounds. For NB(As, Pt) (Figure S10 and Table S3), the As(3d) has a binding energy of 45.0 eV with little shift 
(< 0.5 eV) from those of As2O3 and NaAsO2, indicating As atoms remain at AsIII. For comparison, AsV oxides, such 
as As2O5, have As(3d) at 46-47 eV;[20, 21] intermetallic As0 compounds, such as AsNb and AsGa, have As(3d) at 40-
41 eV.[20] In addition, the Pt(4f7/2) in NB(As, Pt) has a binding energy of 73.5 eV with little shift (< 0.5 eV) from 
those of cisPt and aqua-cisPt, indicating Pt atoms remain at PtII. For comparison, PtIV compounds, such as 
Pt(NH3)6Cl4 and K2PtCl6, have Pt(4f7/2) at 75-77 eV;[20] Pt0 compounds, such as PtSn[23] and PtPd,[24] have Pt(4f7/2) 
at 70-71 eV.  
The complex(As, Pt) formed within liposomes had an As/Pt molar ratio of 1.3 ± 0.1 (n = 7), less than that (1.7 ± 
0.1) in the precipitate from bulk-mixing As(OH)3 with aqua-cisPt acetate under the similar conditions in absence of 
lipids (Figure S9). The extent of arsenic loading and association to Pt appeared to be limited by the barrier of 
liposome membranes. Although the solid complex(As, Pt) tends to hydrolyze when pH > 6.0 (Figure S9), it 
becomes less sensitive to extraliposomal pH once sequestered within the liposome (Figure S3). The acidic 
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intraliposomal conditions (pH 5.1) is likely to be maintained, since the transmembrane pH gradient is difficult to 
change when the liposome system lacks an effective agent to facilitate proton transport from the internal to the 
external medium.[25] 
X-ray Absorption Spectroscopy (XAS) Analysis on NB(As, Pt) 
Aqueous NB(As, Pt) samples were loaded into Lucite cuvettes with 40 µm Kapton windows and rapidly frozen in 
liquid nitrogen. As K-edge and Pt LIII-edge XAS data were collected at Stanford Synchrotron Radiation Laboratory 
(SSRL) on beamline 9-3 (3 GeV, ~90 mA), using a fully-tuned Si(220) double-crystal monochromator with a Rh-
coated mirror upstream of the monochromator for harmonic rejection. As K-edge spectra were measured at 12 K 
using 10 eV increments in the pre-edge region (11635-11845 eV), 0.35 eV for the edge region (11845-11895 eV), 
and 0.05 Å-1 increments for the extended x-ray absorption fine structure (EXAFS) region (1.45 – 16.0 Å-1), with 
integration times of 1 s in the pre-edge and edge regions and 5-25 s (k3 weighted) in the EXAFS region for a total 
scan time of ~42 min. Pt LIII-edge data were measured at 13 K using 10 eV increments in the pre-edge region 
(11335-11545 eV) , 0.5 eV for the edge region (11545-11595 eV), and 0.05 Å-1 increments for the EXAFS region 
(1.77 – 8.5 Å-1), with integration times of 1 s in the pre-edge and edge regions and 5 s (k3 weighted) in the EXAFS 
region for a total scan time of ~10 min. The truncated k-range over which the Pt LIII edge EXAFS data was 
collected is due to the overlap of the Pt LIII EXAFS with the As K edge at 11867.0 eV (Pt LIII k = 8.63 Å-1). 
 
Pt LII XAS data were recorded at SSRL on beamline 7-3, using a fully-tuned Si(220) double-crystal 
monochromator with a Rh-coated mirror upstream of the monochromator for harmonic rejection.. The sample 
temperature was held at 8.5 K in an Oxford liquid He flow cryostat during data collection. Pt LII-edge spectra were 
measured at 7 K using 10 eV increments in the pre-edge region (13040-13250 eV), 0.35 eV for the edge region 
(13250-13300 eV), and 0.05 Å-1 increments for the EXAFS region (1.62 – 12.0 Å-1), with integration times of 1 s in 
the pre-edge and edge regions and 20 s (k3 weighted) in the EXAFS region for a total scan time of ~ 30 min. For all 
samples (on both beamlines), incident intensity was measured using an N2-filled ion chamber and energy 
calibration was performed using foils as internal standards, with the first inflection point of the As foil K-edge 
spectrum defined as 11867 eV, the first inflection point of the Pt foil LIII-edge spectrum defined as 11563 eV, and 
the first inflection point of the Pt foil LII-edge spectrum defined as 13272.3 eV. 
 
As K-edge XAS data were collected as fluorescence excitation spectra using a thirty-element Ge solid-state 
detector array, equipped with a 6 µm Ge filter and Soller slits focused on the Ge detector. The integrated count rate 
for each channel held below ~90 kHz to avoid detector saturation. The windowed As Kα count rates were ~ 19 – 20 
kHz in the EXAFS region, giving a total of ~ 1.3 × 107 – 1.4 × 107 useful counts per scan at k = 16 Å. For all 
samples, each channel of each scan was examined independently for glitches and good channels (27 per scan) were 
averaged to give the final spectrum. Average files for the As K-edge data of NB(As, Pt) samples were calculated 
using 7 scans. 
 
Pt LIII-edge XAS data were collected as fluorescence excitation spectra using a thirty-element Ge solid-state 
detector array, equipped with a 6 µm Ge filter and Soller slits focused on the Ge detector. The Ge filter absorbs the 
elastic scatter while transmitting the Pt fluorescence signal. The integrated count rate for each channel was held 
below ~90 kHz to avoid detector saturation. The windowed Pt Lα1 count rates were ~ 7.9 – 15.6 kHz in the EXAFS 
region, giving a total of ~ 1.1 × 106 – 2.2 × 106 useful counts per scan k = 8.5 Å-1. Measurements were truncated at 
k ~ 8.5 Å-1 due to the presence of the As K edge. For all samples, each channel of each scan was examined 
independently for glitches and good channels (27 per scan) were averaged to give the final spectrum. Average files 
for the Pt LIII-edge data of NB(As, Pt) samples were calculated using 15 scans. 
 
Pt LII-edge XAS data were collected as fluorescence excitation spectra using a thirty-element Ge solid-state 
detector array, equipped with a 3 µm Zn filter and Soller slits focused on the Ge detector. The Zn filter absorbs 
both the elastic scatter and the As Kα emission while transmitting the Pt Lα fluorescence. The integrated count rate 
for each channel was held below ~90 kHz to avoid detector saturation. The windowed Pt Lα1 count rates were ~ 4.8 
kHz in the EXAFS region, giving a total of ~2.7 × 106 counts per scan at k = 12 Å-1. Because a significant fraction 
of the Lα fluorescence originates from excitation of the LIII rather than the LII edge, only a fraction of these counts 
are useful for the LII EXAFS (i.e., there is a much larger than normal background signal, thus accounting for the 
higher noise level of these spectra). For all samples, each channel of each scan was examined independently for 
glitches and good channels (27 per scan) were averaged to give the final spectrum. Average files for the Pt LII-edge 
data of NB(As, Pt) samples were calculated using 21 scans. 
 
X-ray absorption near-edge structure (XANES) data (not shown) were normalized by fitting data to the McMaster 
absorption coefficients below and above the edge using a single background polynomial and scale factor.[26, 27] The 
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EXAFS background correction for both As K-edge and Pt LII and LIII-edge was performed by fitting a three-region 
cubic spline for all samples. The data were then converted to k-space using E0 = 11887 eV for As, and E0 = 13292.3 
eV for Pt. Fourier transforms were calculated using k3 weighted data over ranges of 3.5-15.1 Å-1 (for the As XAS 











sin 2kRas + φas (k)( ), 
 
where χ(k) is the fractional modulation in the absorption coefficient above the edge; Ns is the number of scatters at 
a distance Ras; As(k) is the backscattering amplitude; σas2 is the root-mean-square variation in Ras; ϕas(k) is the phase 
shift experienced by the photoelectron wave in passing through the potentials of the absorbing atom; λ is the mean 
free path of the photoelectron and backscattering atoms; and Ss(k) is a scale factor specific to the absorber-scatterer 
pair. The sum is taken over all scattering interactions.[28] The program Feff version 7.02[29] was used to calculate 
amplitude and phase functions, As(k)exp(-2Ras/λ) and ϕas(k) for As-O and Pt-O/N interactions at 2.0 Å, and Pt-As 
and As-As interactions at 3.0 Å. Data were analyzed in k-space using the program EXAFSPAK.[30] For all data, Ss 
was fixed at 0.9 based on fits to the EXAFS data for structurally characterized model complexes.[31, 32]  
 For As, the data can only be fit using two shells of scatters, one at ~1.7 Å and one at ~2.3 Å, representing As-O and 
a heavier scatterer, respectively. The ~2.3 Å shell could, in principle, be due to As-As, although there is no 
precedent for arsenic oxides with such a short distance. However, fits with As-As are 5-fold worse than fits with 
As-Pt (Tables S4-5). There are additional outer-shell interactions that can be seen in the Fourier transform (Figure 
2g); interpretation of these features will be presented at a later time. 
 
For Pt, the fitting is somewhat ambiguous due to the limited k range. The Fourier transform of the LIII edge data 
shows two higher-R shoulders on the main peak, suggesting that there are three unresolved shells of nearest 
neighbors. Consistent with this, fits using 3 shells (Pt-O/N + Pt-As + Pt-O/N) were attempted. The large peak at ~ 1 
Å in the Fourier transform of the LIII edge data is an artifact of the incomplete background removal that results 
from such a limited k range. Because the Pt LII data was measured to a higher k than the Pt LIII data (Figure S11a), 
the LII data (while noisy) gave more stable fitting results. Therefore, the LII data was used to obtain fitting 
parameters that could be fixed in the fits of the LIII data. Fits of the LII data yielded Pt-O/N distances consistent with 
a four-coordinate Pt complex, a Pt-As distance consistent with the As K-edge data, and reasonable Debye-Waller 
factors. Coordination numbers were constrained to chemically reasonable values. Fits of the LIII data, with Debye-
Waller factors and coordination numbers constrained to those of the Pt LII EXAFS fit, gave distances consistent 
with the other data collected. Because of the limited k-range, it is difficult to distinguish between Pt-As and Pt-Cl 
scattering based solely on the EXAFS; however, Cl was removed by metathesis with silver acetate, as confirmed by 
XPS, thus ruling out Pt-Cl scattering as the source of the ~2.3 Å Pt-X interaction. The near identity of the Pt-As 
distance (from the Pt LII EXAFS) and the As-Pt distance (from the As EXAFS) confirms that this interaction is due 
to a novel Pt-As covalent bond. 
 
Based on these fits and literature precedents, the structure illustrated in Figure S11b is proposed. An alternative 
structure of di-hydroxo/oxo-bridged dinuclear [Pt(µ-O/OH)2As] would not accommodate the very short Pt-As 
distance (~2.3 Å) and As-O and Pt-N/O geometrical restraints. According to literature,[33] the shortest M-M 
distances in di-hydroxy/oxo bridged metal centers are over 2.5 Å. These considerations, plus the structurally 
established precedents of PtII-AsIII Lewis adducts mentioned in the main-text lead us to favor the model shown in 

















Table S4. EXAFS (As-K edge) fitting results for NB(As, Pt) 
 
   First Shell: O/N Second Shell: Pt   
edge Nidp[a] Nvar CN R (Å) σ2 × 103 CN R (Å) σ2 × 103 ∆E0 ξ′[b]
As K 14.77 6[c] 3.3 1.718 2.3 1 2.325 1.7 -11.5 31.8 
k = 3.5 – 15.1  First Shell: O/N Second Shell: As   
R = 0.8 – 2.8  CN R (Å) σ2 × 103 CN R (Å) σ2 × 103 ∆E0 ξ′ 
  6 3.5 1.741 2.5 1 2.313 1.6 -1.68 153 
[a]  Nidp is the number of independent data points in the region of the Fourier transformed spectrum where the data 
are physically meaningful.  The equation Nidp = (2∆k∆R)/π  yields Nidp as a conservative estimate for all above 
samples. 
 [b]  ξ′, mean-square deviation between the k3-weighted data and fit divided by (Nidp–Nvar), where Nvar is the number 
of variables in the fit.  ξ′ values provide a partial correction for the fact that more parameters invariably give better 
fits. Ref [32]. 
 [c]  fitting parameters that were varied are  denoted in italics.  
 
 
Table S5. EXAFS (Pt-LII and Pt-LIII edge) fitting results for NB(As, Pt) 
 
   First Shell: O/N Second Shell: As Third Shell: O   
edge Nidp[a] Nvar CN R (Å) σ2 × 103 CN R (Å) σ2 × 103 CN R (Å) σ2 × 103 ∆E0 ξ′[b]
Pt LII 10.07 7[c] 3 1.977 3.1 1 2.308 1.6 3 3.587 8.7 -12.0 186.8 
k = 2.6 – 10.5             
R = 0.8 – 2.8             
Pt LIII 7.45 4[c] 3 1.996 3.1 1 2.321 1.6 3 3.636 8.7 -10.3 29.5 
k = 2.5 – 8.35             
R = 0.8 – 2.8             
[a]  Nidp is the number of independent data points in the region of the Fourier transformed spectrum where the data are physically meaningful.  
The equation Nidp = (2∆k∆R)/π  yields Nidp as a conservative estimate for all above samples. 
[b]  ξ′, mean-square deviation between the k3-weighted data and fit divided by (Nidp–Nvar), where Nvar is the number of variables in the fit.  ξ′ 
values provide a partial correction for the fact that more parameters invariably give better fits. Ref [32]. 
[c]  fitting parameters that were varied are  denoted in italics. 




















Figure S11. (a) EXAFS spectra and corresponding best fits for NB(As, Pt). Spectra are offset for comparison. (b) Possible
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